|The increase in Replikin Count on the surface of the H1N1 virus|
as the pandemic developed. From Replikins.com
According to Bioradar, the MERS peaked in virulence and infectivity in September of 2012 with a count of 27.7% and dropped sharply to a low of 14.3% by February of 2013. The count began to rise again and as of June, 2013, the last month which data is available, had reached 20%.
The statement stresses that Replikin Counts can change rapidly and the present data is over four months old. They urge specimens be genetically sequenced quickly and results published as soon as possible, ideally within a few days of collection. Replikin analysis should be performed within 24 hours thereafter.
The press release from Bioradar compares the progression of the Replikin Counts in MERS to the SARS outbreak in 2002-2003 and the H1N1 Flu of 2009. It demonstrates a strong correlation between the Replikin peptide levels in the virus and clinical outcomes in the public:
"The rapid quantitative decline here found in Mers CoV gene Replikins resembles that previously found by Replikins Bioradar in the 2002-2003 outbreak of SARS, a coronavirus related to Mers CoV (see Figure). After an abrupt rise in gene Replikin Count in 2002, SARS Replikins began their immediate decline in concentration as the clinical outbreak occurred and quickly terminated in 2003 (1). In another example, this one in real-time gene tracking, the occurrence of the H1N1 pandemic of 2009 was predicted and published one year in advance, its termination in 2009 (see Figure)(1) and its recurrence in 2010, all were predicted by the Replikin Count alone (1-5)."For comparison, this chart shows the Replikin Counts for five strains of influenza and this article reports the numbers for SARS just preceding the 2003 outbreak. It appears that, even at below peak levels, MERS has a significantly higher Replikin Count than either SARS or H1N1.
Elenore and Samuel Bogoch patented a method of identifying replikins in 2001 and the specific group of peptides (short chains of amino acids) was discovered and patented by the company 'Replikins' who trademarked the term 'Replikin Count' and produces synthetic vaccines.